Ocrelizumab and rituximab, both anti-CD20 B-cell monoclonal antibodies, differ in molecular structure and safety profiles, impacting MS treatment outcomes. Retrospective data from the University of ...
From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...
Tafasitamab added to lenalidomide and rituximab reduced progression or death risk by 57% in relapsed/refractory follicular lymphoma patients. The inMIND trial demonstrated significant progression-free ...
Please provide your email address to receive an email when new articles are posted on . Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well-tolerated in relapsed or ...
Off-label rituximab (Rituxan) led to fewer relapses over 2 years than dimethyl fumarate (Tecfidera) in people with early relapsing-remitting multiple sclerosis (MS), the phase III RIFUND-MS trial ...
THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...
Latest U.S. sanction represents fifth for antibody against hematologic cancers. Genentech and Biogen Idec reported receiving an FDA go-ahead for Rituxan® in combination with fludarabine and ...
Primary nephrotic syndrome in adults is characterized by severe proteinuria and hypoalbuminemia. This was the first clinical trial to test rituximab in adult-onset frequently relapsing nephrotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results